✦ LIBER ✦

PMS28 Cost-Benefit-Analysis of Thromboprophylaxis With Rivaroxaban and Certoparin-Sodium in Patients After Total Hip or Knee Replacement

✍ Scribed by K. Heidorn; W. Mittelmeier; G. Kundt; R. Skripitz

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCV11 COST-EFFECTIVENESS OF RIVAROXABAN

✍ Pereira, R; Duran, A; Lindner, L; Toro, W; Arango, CH 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 65 KB

A multi-perspective cost-effectiveness a

✍ Sonja Zindel, Stephanie Stock, Dirk Müller, Björn Stollenwerk 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 934 KB

A Societal Perspective Cost-Utility Anal

✍ Stollenwerk, B.; Le, L.; Zindel, S.; Müller, D.; Klug, F.; Stock, S. 📂 Article 📅 2013 🏛 John Wiley and Sons 🌐 English ⚖ 59 KB

PCV93 THROMBOPROPHYLAXIS AFTER TOTAL KNE

✍ M Lukac; J Bielik; M Lees; D Tomek; V Foltan 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 77 KB

A Cost-Effectiveness Model Comparing Riv

✍ McCullagh, Laura; Tilson, Lesley; Walsh, Cathal; Barry, Michael 📂 Article 📅 2009 🏛 Springer International Publishing AG 🌐 English ⚖ 315 KB

PCV38 COST-EFFECTIVENESS OF RIVAROXABAN

✍ J Kim; R Pollock; S Jung; A Diamantopoulos; M Lees 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 128 KB